Search results for "Adverse reaction"

showing 10 items of 115 documents

Review of current and “omics” methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms

2012

Ethnopharmacological relevance: The increasing use of traditional herbal medicines around the world requires more scientific evidence for their putative harmlessness. To this end, a plethora of methods exist, more or less satisfying. In this post-genome era, recent reviews are however scarce, not only on the use of new "omics" methods (transcriptomics, proteomics, metabonomics) for genotoxicity, teratogenicity, and nephrotoxicity assessment, but also on conventional ones. Methods: The present work aims (i) to review conventional methods used to assess genotoxicity, teratogenicity and nephrotoxicity of medicinal plants and mushrooms; (ii) to report recent progress in the use of "omics" techn…

Proteomicsmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHerbal MedicineOmicsBiologymedicine.disease_causeKidneyToxicologyNephrotoxicity03 medical and health sciences0302 clinical medicineTeratogenicityDrug DiscoverymedicineMethodsHumansTechnology PharmaceuticalIntensive care medicineEvaluationNephrotoxicity030304 developmental biologyPharmacology0303 health sciencesPlants Medicinalbusiness.industrySciences bio-médicales et agricolesOmics3. Good healthBiotechnologyTeratogens030220 oncology & carcinogenesisMedicine TraditionalGenotoxicitybusinessAgaricalesTranscriptomeGenotoxicityPredictive methodsMutagensPhytotherapyJournal of Ethnopharmacology
researchProduct

Drug-induced and iatrogenic infiltrative lung disease.

2004

At present more than 350 drugs are known to cause injury of the lung parenchyma,upper and lower airways, pulmonary circulation, pleura, mediastinum, lymph nodes,and neuromuscular system. Infiltrative lung disease (ILD) is the most common pattern of drug-induced injury. This article, which is clinically oriented rather than drug oriented, reviews the patterns of ILD produced by therapeutic drugs and radiation therapy.

Pulmonary and Respiratory MedicineDrugLung Diseasesmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectIatrogenic DiseaseMEDLINEAmiodaronePulmonary EdemaSarcoidosis PulmonaryIatrogenic diseaseMedicineHumansIntensive care medicinemedia_commonbusiness.industryPneumoniamedicine.diseaseBreast radiationDermatologyPulmonary AlveoliMethotrexateLung diseaseSarcoidosisbusinessAnti-Arrhythmia AgentsClinics in chest medicine
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

USE OF HERBAL REMEDIES AMONG CANCER AND TRANSPLANT PATIENTS IN THE TOWN OF PALERMO, SICILY

2010

Concomitant use of herbal remedies may lead to toxicity or failure of conventional therapies in different patients. The objectives of this survey were to assess: (1) the prevalence of the use of vegetal remedies by cancer and transplanted patients (2) the level of communication about such use to the physicians (3) whether such use might be associated to adverse reactions or interactions with conventional drugs. The study was carried out on 100 consecutive cancer patients attending the outpatient medical oncology clinic of the University Hospital "P. Giaccone", Palermo and on other 100 transplanted patients who were hospitalized or followed up at ISMETT, Palermo. Another group was composed o…

Settore MED/06 - Oncologia MedicaSettore BIO/14 - FarmacologiaHerbal medicines oncology trasplantation adverse reactions interactions aloe
researchProduct

Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update

2020

CTLA-4 and PD-1 play a key role in tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti-CTLA-4 and anti-PD-1 antibodies affect the interaction between tumor, antigen-presenting cells and T lymphocytes. Clinical studies of the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five-year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with …

Skin NeoplasmsDrug-Related Side Effects and Adverse ReactionsSide effectProgrammed Cell Death 1 ReceptorMedizinIpilimumabDermatologyPembrolizumabAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenImmune Checkpoint InhibitorsMelanomabusiness.industryMelanomamedicine.diseaseCombined Modality TherapyIpilimumabImmune checkpoint3. Good healthNivolumabCTLA-4ImmunologyImmunotherapyNivolumabbusinessmedicine.drug
researchProduct

Quality of life improving after propranolol treatment in patients with Infantile Hemangiomas

2022

AbstractInfantile hemangiomas may affect the quality of life (QoL) of patients and their family members, as anxiety and worry may commonly occur in parents, also linked to the social adversion they experience. We underline the beneficial impact of oral propranolol therapy on QoL of patients with infantile hemangiomas (IH) and of their relatives. A specific questionnaire measuring QoL was administered to parents of IH patients at beginning and end of a treatment with oral propranolol. Different aspects were investigated: site of the lesion, age of patients at starting therapy, length of treatment, occurrence of adverse effects and persistence/recurrence of the vascular anomaly. In all cases …

Skin NeoplasmsTreatment OutcomeDrug-Related Side Effects and Adverse ReactionsSurveys and QuestionnairesQuality of LifeAdministration OralHumansInfantHemangioma CapillaryGeneral MedicinePropranololIH Quality of life Pediatric benign tumors Propranolol Questionnaire
researchProduct

Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy

2011

A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…

SorafenibNiacinamideMalemedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsPyridinesAntineoplastic AgentsEPATOCARCINOMAlaw.inventionRandomized controlled triallawDrug ToxicityInternal medicinemedicineHumansProspective StudiesHCCProspective cohort studySurvival analysisAgedHCC; sorafenibHepatologybusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularSorafenibMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryHepatocellular carcinoma sorafenibRegimenTUMORI DEL FEGATOTolerabilityItalyHepatocellular carcinomaDisease ProgressionsorafenibFemaleLiver cancerbusinessmedicine.drug
researchProduct

Multi-omics HeCaToS dataset of repeated dose toxicity for cardiotoxic & hepatotoxic compounds.

2022

The data currently described was generated within the EU/FP7 HeCaToS project (Hepatic and Cardiac Toxicity Systems modeling). The project aimed to develop an in silico prediction system to contribute to drug safety assessment for humans. For this purpose, multi-omics data of repeated dose toxicity were obtained for 10 hepatotoxic and 10 cardiotoxic compounds. Most data were gained from in vitro experiments in which 3D microtissues (either hepatic or cardiac) were exposed to a therapeutic (physiologically relevant concentrations calculated through PBPK-modeling) or a toxic dosing profile (IC20 after 7 days). Exposures lasted for 14 days and samples were obtained at 7 time points (therapeutic…

Statistics and ProbabilityEpigenomicsProteomicsBioquímicaBiologiaDrug-Related Side Effects and Adverse ReactionsLibrary and Information SciencesCardiotoxicityComputer Science ApplicationsEducationHumansMetabolomicsStatistics Probability and UncertaintyTranscriptomeInformation Systems
researchProduct

Vakcinācija priekšlaikus un laikā dzimušajiem bērniem Latvijā

2019

Ievads: Vakcinācija būtiski samazinājusi daudzu nopietnu slimību izplatību pasaulē. Lai gan priekšlaikus dzimuši zīdaiņi ir vairāk jutīgi pret infekcijām, viņu vakcinācija bieži vien tiek atlikta vai arī veikta pēc atvieglinātas programmas. Tā kā imunizācija Latvijā nav obligāta, ir nepieciešams pētījums, kurš ļaus atklāt aktuālas vakcinācijas tendences un faktorus, kas varētu uzlabot vakcinācijas pārklājumu. Mērķis: Šī pētījuma mērķis bija vakcināciju tendenču salīdzinājums priekšlaikus un laikā dzimušiem bērniem ar anonīmas vecāku aptauju. Metodoloģija: Bērnu (līdz pieciem gadiem) vecāki aizpildīja anketu (bērnu vecumu, dzimumu, dzimšanas datus un veselības stāvokli, pēcdzemdību hospitali…

VaccinationVakcinācijaPrematurityAdverse reactionsPriekšlaikus dzimuši bērniMedicīna
researchProduct

Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SA…

2021

The main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first dose of anti-SARS CoV2 vaccine. For 5 h after the administration of the vaccine, she had the appearance of erythematous spots on the face and neck, and a feeling of a slurred mouth and hoarseness. In order to treat the event, she was administered 8 mg intravenous dexamethasone, 1 vial intravenous chlorphenamine maleate, 250 mL intravenous 0.9% NaCl, and conventional oxygen therapy (2 L/min) with co…

medicine.medical_specialtyAllergyImmunologyadverse reactionCase ReportVial03 medical and health sciences0302 clinical medicineInternal medicinevaccineDrug DiscoverymedicineanaphylaxisPharmacology (medical)030212 general & internal medicineAdverse effectContraindicationDexamethasonePharmacologym-RNA vaccinebusiness.industrySARS CoV2Rmedicine.diseasePEGAdverse reaction Anaphylaxis Basophil activation test Contraindica-tion M-RNA vaccine PEG SARS CoV2 VaccineVaccinationInfectious Diseases030228 respiratory systembasophil activation testMedicinebusinessAnaphylaxisAdverse drug reactioncontraindicationmedicine.drugVaccines
researchProduct